AstraZeneca gets CDSCO nod for lung cancer drug
New Delhi: AstraZeneca India Pharma on Thursday said it has received approval from the Central Drugs Standard Control Organisation (CDSCO) for Osimertinib tablets in strength of 40mg and 80mg. The approval marks a critical step forward with Osimertinib as monotherapy in the treatment of patients with locally advanced, unresectable (Stage III) non-small cell lung cancer, it added.
Next Story
Woman injured in stabbing attack in Tokyo, suspect at large
Bengal cop booked for murder over mysterious death of woman home guard, SIT to probe case
Staffer recalls horror of 7-kg gold robbery by armed gang in Karnataka’s Hunsur
25-Year-Old Airline Cabin Crew Member Dies At Gurugram Party; Police Begin Investigation
